Hikma delivers another strong financial and operational performance, and improves FY outlook for Generics

Hikma delivers another strong financial and operational performance, and improves FY outlook for Generics

London, United Kingdom, (AETOSWire) – Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its interim results for the six months ended 30 June 2021. Siggi Olafsson, Chief Executive Officer of Hikma, said: “Once again, we have benefited from the resilience of our portfolio and our flexible manufacturing footprint. Our strong performance included solid year-over-year increases in revenue and operating profit, underscoring our ability to generate positive results in challenging market conditions. We are continuing to benefit from investments we have made to build our pipeline of…